Premium
Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group
Author(s) -
Dreicer Robert,
Roth Bruce,
Wilding George
Publication year - 2003
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.11298
Subject(s) - medicine , urothelial cancer , urothelium , oncology , clinical trial , chemotherapy , cancer , malignancy , bladder cancer , clinical oncology , transitional cell carcinoma , disease , urinary bladder
Advanced transitional cell carcinoma of the urothelium is an aggressive malignancy characterized by a median survival period of less than 1 year. Although this disease is moderately chemotherapy‐sensitive, to the authors' knowledge the impact of therapy reported to date on survival has been minimal. The authors presented an overview of the results from a series of clinical trials conducted over a 25‐year period under the auspices of the Eastern Cooperative Oncology Group. They reviewed a series of antineoplastic agents identified by these studies with activity in advanced urothelial cancer and discussed current and future investigational goals and directions. Cancer 2003;97(8 Suppl):2109–14. © 2003 American Cancer Society. DOI 10.1002/cncr.11298